Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC
(MedPage Today) -- Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to a phase II trial from...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer